- Home
- NVGS vs SNDX Comparison
NVGS vs SNDX Comparison
Compare NVGS & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVGS
- SNDX
- Stock Information
- Founded
- NVGS 1997
- SNDX 2005
- Country
- NVGS United Kingdom
- SNDX United States
- Employees
- NVGS N/A
- SNDX N/A
- Industry
- NVGS Marine Transportation
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- NVGS Consumer Discretionary
- SNDX Health Care
- Exchange
- NVGS Nasdaq
- SNDX Nasdaq
- Market Cap
- NVGS 994.3M
- SNDX 1.1B
- IPO Year
- NVGS N/A
- SNDX 2016
- Fundamental
- Price
- NVGS $15.30
- SNDX $9.34
- Analyst Decision
- NVGS Strong Buy
- SNDX Strong Buy
- Analyst Count
- NVGS 3
- SNDX 11
- Target Price
- NVGS $22.00
- SNDX $34.00
- AVG Volume (30 Days)
- NVGS 774.5K
- SNDX 2.0M
- Earning Date
- NVGS 08-13-2025
- SNDX 07-31-2025
- Dividend Yield
- NVGS 1.29%
- SNDX N/A
- EPS Growth
- NVGS 9.28
- SNDX N/A
- EPS
- NVGS 1.27
- SNDX N/A
- Revenue
- NVGS $583,931,000.00
- SNDX $43,722,000.00
- Revenue This Year
- NVGS $3.45
- SNDX $431.08
- Revenue Next Year
- NVGS N/A
- SNDX $105.38
- P/E Ratio
- NVGS $12.18
- SNDX N/A
- Revenue Growth
- NVGS 6.38
- SNDX N/A
- 52 Week Low
- NVGS $10.55
- SNDX $8.58
- 52 Week High
- NVGS $17.53
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- NVGS 60.19
- SNDX 51.90
- Support Level
- NVGS $15.20
- SNDX $8.59
- Resistance Level
- NVGS $15.58
- SNDX $10.01
- Average True Range (ATR)
- NVGS 0.40
- SNDX 0.51
- MACD
- NVGS 0.03
- SNDX 0.15
- Stochastic Oscillator
- NVGS 79.10
- SNDX 87.46
About NVGS Navigator Holdings Ltd. (Marshall Islands)
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.